Search results for "BUP"

showing 10 items of 168 documents

Effects of acute bupropion administration on locomotor activity in adolescent and adult mice

2005

Responses to some psychoactive substances seem to differ between adolescents and adults. Bupropion, an antidepressant which is also used for smoking cessation, induces a dose-dependent increase in locomotor activity in adult mice, although its behavioral actions in adolescents have not been evaluated. In the present study the effects of acute bupropion administration (5, 10, 15 and 20 mg/kg) on locomotor activity were examined in early adolescent (postnatal day (pnd): 29-31 days), late adolescent (pnd: 47-49 days) and adult (pnd > 70 days) male NMRI mice, using an infrared photocell system. Locomotion was recorded for a total period of 90 min. Results indicated that there were significant d…

MaleAgingTime FactorsEarly adolescencemedicine.medical_treatmentPhysiologyMotor ActivityPharmacologyLocomotor activityMiceDopamine Uptake Inhibitorsmental disordersmedicineAnimalsBupropionPharmacologyBupropionDose-Response Relationship DrugLate adolescencePsychiatry and Mental healthDose–response relationshipSmoking cessationAntidepressantEarly adolescentsPsychologymedicine.drugBehavioural Pharmacology
researchProduct

Bupropion induced changes in exploratory and anxiety-like behaviour in NMRI male mice depends on the age

2013

The aim of this study was to assess the effects of the antidepressant bupropion on anxiety and novelty-seeking in adolescent mice of different ages and adults. Behavioural differences between early adolescent, late adolescent and adult NMRI mice were measured both in the elevated plus-maze and the hole-board tasks following acute administration of bupropion (5, 10, 15, 20 mg/kg) or saline. In the plus maze test, early and late adolescent mice treated with bupropion (10, 15 mg/kg, respectively) had lower percentages of entries in the open-arms compared to their vehicle controls. Adult mice treated with bupropion did not differ from their vehicle controls. These results suggest that the effec…

MaleAgingmedicine.medical_specialtyElevated plus mazeHole-boardDEFICIT HYPERACTIVITY DISORDERmedicine.medical_treatmentAnxietySUBSTANCE USE DISORDERSINDIVIDUAL-DIFFERENCESHOLE-BOARD TESTMiceBehavioral NeuroscienceADULT RATSInternal medicinemedicineAnimalsSOCIAL-BEHAVIORMaze LearningPsychiatryBupropionBupropionHole-board testDose-Response Relationship DrugLOCOMOTOR-ACTIVITYNovelty seekingELEVATED PLUS-MAZEGeneral MedicineSMOKING-CESSATIONNICOTINE DEPENDENCEAdolescenceEndocrinologyNovelty-seekingAnxiogenicExploratory BehaviorAntidepressive Agents Second-GenerationSmoking cessationAntidepressantAnxietyAnimal Science and Zoologymedicine.symptomPsychologypsychological phenomena and processesmedicine.drugBehavioural Processes
researchProduct

Effects of bupropion, alone or coadministered with nicotine, on social behavior in mice

2008

Bupropion, administered alone or combined with nicotine, is presently used to treat nicotine dependence. Despite experimental evidence of the complex behavioral actions of this drug, there have been little data reported about its effects on social behavior. Our main aim was to investigate the effects of acute administration of bupropion, alone or plus nicotine, on social interaction in mice. OF1 group-housed male mice were confronted in a neutral cage with an anosmic opponent during a 10 minutes encounter. Time allocated to body care and digging was reduced by administration of bupropion (40 mg/kg) both when administered alone and with nicotine (1 and 0.5 mg/kg). The lowest dose of bupropio…

MaleDrugNicotinemedicine.drug_classmedia_common.quotation_subjectMedicine (miscellaneous)Male miceAnxietyPharmacologyAnxiolyticDrug Administration ScheduleNicotineMiceDopamine Uptake Inhibitorsmental disordersmedicineAnimalsSocial BehaviorNicotine dependenceBupropionmedia_commonPharmacologyBupropionBehavior AnimalLow doseTobacco Use Disordermedicine.diseaseGanglionic StimulantsAggressionPsychiatry and Mental healthExploratory BehaviorPsychologymedicine.drugAddiction Biology
researchProduct

Effects of co-administration of bupropion and nicotinic agonists on the elevated plus-maze test in mice

2005

There is evidence that the cholinergic nicotinic system is involved in the modulation of anxiety. Anxiolytic and anxiogenic effects of nicotine agonists have been reported in mice. Bupropion is an antidepressant drug which may alleviate some symptoms of nicotine withdrawal, although its effects on anxiety are not clear. It has been suggested that the interaction between bupropion and nicotinic mechanisms could be complex. The aim of the present study was to investigate acute effects of co-administration of bupropion and nicotinic agonists on the elevated plus-maze test in NMRI mice. Effects of nicotine, lobeline, and cytisine (0.35 and 0.175 mg/kg), administered alone or combined with bupro…

MaleElevated plus mazemedicine.drug_classPharmacologyAnxiolyticNicotineMicechemistry.chemical_compoundDopamine Uptake Inhibitorsmental disordersmedicineAnimalsLobelineNicotinic AgonistsMaze LearningBupropionBiological PsychiatryPharmacologyBupropionAnalysis of VarianceBehavior AnimalDose-Response Relationship Drugbusiness.industrymedicine.diseaseDrug CombinationsNicotinic agonistNicotine withdrawalchemistryAnxiogenicbusinesspsychological phenomena and processesmedicine.drugProgress in Neuro-Psychopharmacology and Biological Psychiatry
researchProduct

Dexketoprofen/tramadol: randomised double-blind trial and confirmation of empirical theory of combination analgesics in acute pain

2015

Background Combination analgesics are effective in acute pain, and a theoretical framework predicts efficacy for combinations. The combination of dexketoprofen and tramadol is untested, but predicted to be highly effective. Methods This was a randomised, double-blind, double-dummy, parallel-group, placebo-controlled, single-dose trial in patients with moderate or severe pain following third molar extraction. There were ten treatment arms, including dexketoprofen trometamol (12.5 mg and 25 mg) and tramadol hydrochloride (37.5 mg and 75 mg), given as four different fixed combinations and single components, with ibuprofen 400 mg as active control as well as a placebo control. The study objecti…

MaleKetoprofenWisdom toothEmpirical Researchlaw.inventionPostoperative painDolor postoperatoriRandomized controlled triallawDose rangeAntiinflammatory agentsTromethamineTramadolRandomised controlled trialAnalgesicsAnti-Inflammatory Agents Non-SteroidalAgents antiinflamatorisQueixal del senyGeneral MedicineMiddle AgedIbuprofenAcute PainAnalgesics OpioidKetoprofenAnesthesiaTramadol HydrochlorideDrug Therapy CombinationFemaleTramadolResearch Articlemedicine.drugAdultAdolescentAnalgesicClinical NeurologyPlaceboOdontologiaYoung AdultAnalgèsicsDouble-Blind MethodThird molarPosologymedicineDexketoprofenHumansPain ManagementCombination analgesicsbusiness.industryDexketoprofenPosologiaAnesthesiology and Pain MedicineDentistryNeurology (clinical)Analgesiabusiness
researchProduct

A prospective, randomized, triple-blind comparison of articaine and bupivacaine for maxillary infiltrations

2011

Objectives: To compare the clinical anesthetic efficacy of 0.5% bupivacaine and 4% articaine (both with 1:200.000 adrenaline) for anterior maxillary infiltration in healthy volunteers. Material and methods: A triple-blind split-mouth randomized clinical trial was carried out in 20 volunteers. A supraperiosteal buccal injection of 0.9 ml of either solution at the apex of the lateral incisor was done in 2 appointments separated 2 weeks apart. The following outcome variables were measured: latency time, anesthetic efficacy (dental pulp, keratinized gingiva, alveolar mucosa and upper lip mucosa and tissue) and the duration of anesthetic effect. Hemodynamic parameters were monitored during the p…

MaleLocal anesthesiaAnestèsia en odontologiaTime FactorsLidocaineAnesthesia DentalDentistryJawsCarticaineArticaineInjectionsYoung AdultCarticainestomatognathic systemMaxillamedicineHumansProspective StudiesAnesthetics LocalGeneral DentistryAlveolar mucosaBupivacaineMaxil·larsbusiness.industryClinical and Experimental dentistryHemodynamicsLidocaineAnestèsia localBuccal administration:CIENCIAS MÉDICAS [UNESCO]AmidesInjeccionsstomatognathic diseasesOtorhinolaryngologyResearch DesignAnesthesiaMaxillaUNESCO::CIENCIAS MÉDICASAnestheticResearch-ArticleFemaleSurgeryAnesthesia in dentistrybusinessAnesthesia Localmedicine.drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

The anti-inflammatory drugs diclofenac, naproxen and ibuprofen are found in the bile of wild fish caught downstream of a wastewater treatment plant.

2012

Pharmaceutical residues are ubiquitous in rivers, lakes, and at coastal waters affected by discharges from municipal wastewater treatment plants. In this study, the presence of 17 different pharmaceuticals and six different phase I metabolites was determined in the bile of two wild fish species, bream (Abramis brama) and roach (Rutilus rutilus). The fish were caught from a lake that receives treated municipal wastewater via a small river. Prior to analyses, the bile content was enzymatically hydrolyzed to convert the glucuronide metabolites into the original pharmaceuticals or phase I metabolites. The solid phase extracts of hydrolyzates were analyzed by liquid chromatography-tandem mass sp…

MaleNaproxenDiclofenacmedicine.drug_classta1172CyprinidaeIbuprofenWaste Disposal FluidAnti-inflammatoryDiclofenacNaproxenmedicineEnvironmental ChemistryAnimalsBileEffluentChromatographybiologyAnti-Inflammatory Agents Non-SteroidalGeneral Chemistrybiology.organism_classificationLakesWastewaterFemaleRutilusGlucuronideWater Pollutants Chemicalmedicine.drugWaste disposalEnvironmental MonitoringEnvironmental sciencetechnology
researchProduct

Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone

2021

International audience; Aim: To explore the factors determining the interest in extended-release buprenorphine (XR-BUP) injections among patients receiving opioid agonist treatment (OAT) in France.Methods: 366 patients receiving OAT for opioid use disorder, recruited in 66 French centers, were interviewed from 12/2018 to 05/2019. A structured questionnaire assessed their interest in XR-BUP using a [1-10] Likert scale. 'More' vs. 'less' interested groups were defined using the median score of interest, and their characteristics were explored using adjusted odds ratios (aORs) and 95 % confidence interval (95 %CI). Independent variables were as follows: sociodemographic characteristics, OAT-re…

MaleNarcotic Antagonists[SDV]Life Sciences [q-bio]ToxicologyMESH: Analgesics Opioid0302 clinical medicineInterquartile rangeSurveys and QuestionnairesPharmacology (medical)030212 general & internal medicineSurveymedia_commonMESH: Patient PreferenceMESH: Middle AgedOpioid use disorderPatient PreferenceMiddle AgedBuprenorphineAnalgesics OpioidPsychiatry and Mental healthMESH: Young AdultFemaleFranceMESH: Narcotic AntagonistsPatients' preferencemedicine.drugAdultmedicine.medical_specialtyAdolescentMESH: Delayed-Action Preparationsmedia_common.quotation_subjectMESH: BuprenorphineMESH: Opiate Substitution TreatmentInjections03 medical and health sciencesYoung AdultInternal medicinemedicineOpiate Substitution TreatmentHumansMESH: InjectionsDosingMESH: Surveys and QuestionnairesPharmacologyMESH: AdolescentMESH: Humansbusiness.industryMESH: AdultOdds ratioAbstinencemedicine.diseaseOpioid-Related DisordersConfidence intervalMESH: MaleMESH: Opioid-Related DisordersMESH: FranceDelayed-Action PreparationsMESH: MethadoneExtended-releasebusinessMESH: Female030217 neurology & neurosurgeryMethadoneMethadoneBuprenorphine
researchProduct

Xenon improves long-term cognitive function, reduces neuronal loss and chronic neuroinflammation, and improves survival after traumatic brain injury …

2019

Background.Xenon is a noble gas with neuroprotective properties. We previously showed that xenon improves short and long-term outcomes in young adult mice after controlled cortical impact (CCI). This is a follow-up study investigating xenon’s effect on very long-term outcome and survival. Methods.C57BL/6N (n=72) young adult male mice received single CCI or sham surgery and were treated with either xenon (75%Xe:25%O2) or control gas (75% N2:25%O2). The outcomes used were: 1) 24-hour lesion volume and neurological outcome score; 2)contextual fear-conditioning at 2 weeks and 20 months; 3) corpus callosum white matter quantification; 4) immunohistological assessment of neuroinflammation and neu…

MaleXenonhippocampusnerve degenerationCorpus callosumBUPRENORPHINEneuroinflammationMice0302 clinical medicineCognition030202 anesthesiologyAnesthesiologyBrain Injuries TraumaticMedicineEPIDEMIOLOGYYoung adultmemory disordersNeuronstraumatic brain injurySham surgeryBrain3. Good healthD-ASPARTATE RECEPTORmedicine.anatomical_structureNeuroprotective AgentsAnesthesianeuroprotectionmedicine.symptomLife Sciences & BiomedicineTraumatic brain injuryHYPOPITUITARISMNeuroprotectionWhite matter03 medical and health sciencesANALGESIAINHALED XENONAnimalsgeneral anaesthesiaSurvival analysisHYPOTHERMIAInflammationScience & Technologybusiness.industry1103 Clinical SciencesHypothermiamedicine.diseaseCOMPETITIVE-INHIBITIONSurvival AnalysisMice Inbred C57BLPATHOLOGYDisease Models AnimalAnesthesiology and Pain MedicineChronic DiseasebusinessCognition Disorders030217 neurology & neurosurgeryWHITE-MATTER DAMAGEFollow-Up StudiesBritish journal of anaesthesia
researchProduct

Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: A 4-week, nonrandomized, open-label, uncontrolled observational stu…

2009

OBJECTIVE: The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) buprenorphine patches in opioid-naive patients with cancer pain. METHODS: This was a nonrandomized, open-label, uncontrolled study in consecutive opioid-naive patients with advanced cancer and moderate pain. TD buprenorphine was initiated at a dose of 17.5 microg/h (0.4 mg/d), with patch changes every 3 days. Doses were then adjusted according to the clinical response. Pain intensity, opioid-related adverse effects, TD buprenorphine doses, and quality of life were monitored over 4 weeks. The time to dose stabilization and indexes of dose escalation were also calculated. RESULTS: Thi…

Malecancer painPainOpioidUncontrolled Studytransdermal buprenorphine cancer pain uncontrolled observational studyDose-Response RelationshipNeoplasmsmedicineHumansPharmacology (medical)Adverse effectAgedPain MeasurementIntractablePharmacologyAnalgesicsbusiness.industryopioidsCancermorphineMiddle Agedbuprenorphine; cancer pain; morphine; opioids; Administration Cutaneous; Aged; Analgesics Opioid; Buprenorphine; Dose-Response Relationship Drug; Female; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Pain Intractable; Quality of Life; Pharmacology; Pharmacology (medical)buprenorphinemedicine.diseaseClinical trialCutaneousTolerabilityAnesthesiaAdministrationQuality of LifeMorphineFemaleDrugCancer painbusinessmedicine.drugBuprenorphineClinical Therapeutics
researchProduct